Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: First clinical results

British Journal of Cancer

Volumn 109, Issue 4, 2013, Pages 934-942

  Schoffelen, R ^a   Boerman, O C ^a   Goldenberg, D M ^b,c   Sharkey, R M ^c   Van Herpen, C M L ^a   Franssen, G M ^a   McBride, W J ^c   Chang, C H ^c   Rossi, E A ^c   Van Der Graaf, W T A ^a   Oyen, W J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^c IMMUNOMEDICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CLEMASTINE; DEXAMETHASONE; GAMMA GLUTAMYLTRANSFERASE; HAPTEN; IMP 288; IMP 288 IN 111; IMP 288 LU 177; INDIUM 111; LUTETIUM 177; MONOCLONAL ANTIBODY TF2; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALBUMIN BLOOD LEVEL; ANOREXIA; ARTHRITIS; ARTICLE; BACKACHE; BILIARY TRACT INFECTION; BLOOD TOXICITY; BONE MARROW TOXICITY; BONE METASTASIS; CANCER PAIN; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIAGNOSTIC IMAGING; DIARRHEA; DOSIMETRY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOXIA; INFUSION RELATED REACTION; ISOTOPE LABELING; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROLOGIC DISEASE; PERITONEUM METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOACTIVITY; RADIOISOTOPE THERAPY; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SKIN MANIFESTATION; SOFT TISSUE METASTASIS; SOMNOLENCE; SWEATING; THORAX PAIN; THROMBOCYTOPENIA; URINARY FREQUENCY; WHOLE BODY SCINTISCANNING;

ADULT; AGED; ANTIBODIES, BISPECIFIC; CARCINOEMBRYONIC ANTIGEN; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; GPI-LINKED PROTEINS; HAPTENS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; RADIOIMMUNOTHERAPY;

EID: 84883173479     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.376     Document Type: Article

References (39)

1. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10): 1626-1634.
2. Baum RP, Rosch F (2011) 1 World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy (PRRNT), June 23-26, 2011, Zentralklinik Bad Berka, Germany. World J Nucl Med 10(1): 1-2.
3. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH (2003) Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 44(3): 400-411.
4. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27(5): 663-671.
5. Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W, Hansen HJ, Chatal JF, Barbet J, Goldenberg DM (2002) Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther 1(7): 553-563.
6. Chatal JF, Campion L, Kraeber-Bodere F, Bardet S, Vuillez JP, Charbonnel B, Rohmer V, Chang CH, Sharkey RM, Goldenberg DM, Barbet J (2006) Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-Antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 24(11): 1705-1711.
7. Chinn PC, Morena RA, Santoro DA, Kazules T, Kashmiri SV, Schlom J, Hanna N, Braslawsky G (2006) Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft. Cancer Biother Radiopharm 21(2): 106-116.
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2): 228-247.
9. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson 3rd AB (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12): 1539-1544.
10. Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH (2008) Multifunctional antibodies by the Dock-And-Lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 49(1): 158-163.
11. Gordon LI, Witzig T, Molina A, Czuczman M, Emmanouilides C, Joyce R, Vo K, Theuer C, Pohlman B, Bartlett N, Wiseman G, Darif M, White C (2004) Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma 5(2): 98-101.
12. Govindan SV, Goldenberg DM (2010) New antibody conjugates in cancer therapy. ScientificWorldJournal 10: 2070-2089.
13. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23): 2335-2342.
14. Jain RK (1990) Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 50(3 Suppl): 814s-819s.
15. Karacay H, McBride WJ, Griffiths GL, Sharkey RM, Barbet J, Hansen HJ, Goldenberg DM (2000) Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide. Bioconjug Chem 11(6): 842-854.
16. Kraeber-Bodere F, Bardet S, Hoefnagel CA, Vieira MR, Vuillez JP, Murat A, Ferreira TC, Bardies M, Ferrer L, Resche I, Gautherot E, Rouvier E, Barbet J, Chatal JF. (1999) Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin Cancer Res 5(10 Suppl): 3190s-3198s.
17. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J (1989) In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med 30(8): 1358-1366.
18. Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, Ghadimi BM, Wegener WA, Kovacs J, Horak ID, Becker H, Goldenberg DM (2005) Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol 23(27): 6763-6770.
19. Losman MJ, Novick KE, Goldenberg DM, Monestier M (1994) Mimicry of a carcinoembryonic antigen epitope by a rat monoclonal anti-idiotype antibody. Int J Cancer 56(4): 580-584.
20. McBride WJ, Zanzonico P, Sharkey RM, Noren C, Karacay H, Rossi EA, Losman MJ, Brard PY, Chang CH, Larson SM, Goldenberg DM (2006) Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J Nucl Med 47(10): 1678-1688.
21. Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, Bekaii-Saab T, Serafini AN, Lee D, Sung MW, Gulec SA, Goldsmith SJ, Manzone T, Holt M, O'Neil BH, Hall N, Montero AJ, Kauh J, Gold DV, Horne H, Wegener WA, Goldenberg DM (2012) Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial. Cancer 118(22): 5497-5506.
22. Reardan DT, Meares CF, Goodwin DA, McTigue M, David GS, Stone MR, Leung JP, Bartholomew RM, Frincke JM (1985) Antibodies against metal chelates. Nature 316(6025): 265-268.
23. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH (2006) Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA 103(18): 6841-6846.
24. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26(12): 2013-2019.
25. Schoffelen R, Boerman OB, van der Graaf WTA, van Herpen CML, McBride WJ, Chang C-H, Rossi EA, Goldenberg DM, Oyen WJG (2011) Phase I clinical study of the feasibility of pretargeted radioimmunotherapy (PT-RAIT) in patients with colorectal cancer (CRC): first results. J Nucl Med 52(Suppl 1): 358.
26. Schoffelen R, Sharkey RM, Goldenberg DM, Franssen G, McBride WJ, Rossi EA, Chang CH, Laverman P, Disselhorst JA, Eek A, van der Graaf WT, Oyen WJ, Boerman OC (2010a) Pretargeted immunopositron emission tomography imaging of carcinoembryonic antigenexpressing tumors with a bispecific antibody and a 68Ga-And 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther 9(4): 1019-1027.
27. Schoffelen R, van der Graaf WT, Franssen G, Sharkey RM, Goldenberg DM, McBride WJ, Rossi EA, Eek A, Oyen WJ, Boerman OC (2010b) Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigenexpressing human colonic tumors in mice. J Nucl Med 51(11): 1780-1787.
28. Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, McBride WJ, Hansen HJ, Horak ID, Goldenberg DM (2005) Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 11(11): 1250-1255.
29. Sharkey RM, Goldenberg DM (2011) Cancer radioimmunotherapy. Immunotherapy 3(3): 349-370.
30. Sharkey RM, Karacay H, Litwin S, Rossi EA, McBride WJ, Chang CH, Goldenberg DM (2008) Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res 68(13): 5282-5290.
31. Sharkey RM, Karacay H, Richel H, McBride WJ, Rossi EA, Chang K, Yeldell D, Griffiths GL, Hansen HJ, Goldenberg DM (2003a) Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res 9(10 Pt 2): 3897S-3913SS.
32. Sharkey RM, McBride WJ, Karacay H, Chang K, Griffiths GL, Hansen HJ, Goldenberg DM (2003b) A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res 63(2): 354-363.
33. Sharkey RM, Rossi EA, McBride WJ, Chang CH, Goldenberg DM (2010) Recombinant bispecific monoclonal antibodies prepared by the dock-Andlock strategy for pretargeted radioimmunotherapy. Semin Nucl Med 40(3): 190-203.
34. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Borger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360(6): 563-572.
35. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14): 1408-1417.
36. Vuillez JP, Kraeber-Bodere F, Moro D, Bardies M, Douillard JY, Gautherot E, Rouvier E, Barbet J, Garban F, Moreau P, Chatal JF (1999) Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/antidiethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial. Clin Cancer Res 5(10 Suppl): 3259s-3267s.
37. Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, Schilder RJ, Murray JL, Saleh M, Allen RS, Grillo-Lopez AJ, White CA (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99(12): 4336-4342.
38. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, Cripe L, Wiseman G, Olejnik T, Multani PS, White CA (2002a) Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20(15): 3262-3269.
39. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-Lopez AJ, Multani P, White CA (2002b) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20(10): 2453-2463.